Tab. II.
VGT n (%) |
Placebo n (%) |
TIV1 n (%) |
TIV2 n (%) |
|
---|---|---|---|---|
Numero di soggetti randomizzati | 2.721 | 2.715 | 183 | 186 |
FASE (Full Analysis Set Efficacy) | 2.584 (95,0) | 2.591 (95,4) | NA | NA |
PPE (Per Protocol analysis set Efficacy) | 2.489 (91,5) | 2.491 (91,7) | NA | NA |
PPI (Per Protocol analysis for Immunogenicity) | 300 (81,7) | 308 (84,6) | 152 (83,1) | 168 (90,3) |